Precision Vaccines: Lessons Learned From the Coronavirus Pandemic
- PMID: 35439282
- PMCID: PMC9376275
- DOI: 10.1093/cid/ciac300
Precision Vaccines: Lessons Learned From the Coronavirus Pandemic
Conflict of interest statement
Potential conflicts of interest. S. A. P has received funding from Merck, GSK, NovaVax, Takeda, NTx, Vaxart, Moderna, NewLink, OmVax, XVax, Valneva, and Sanofi. E. R. W. has received support from the National Institute for Allergy and Infectious Diseases (NIAID) for the development of vaccines for the treatment of opioid use disorder (contract number 75N93020C00038) and from the National Institutes of Health (NIH) (contract number HHSN272201800047C). O. L. has received support from the NIH/NIAID for a vaccine adjuvant discovery program (contract number HHSN272201800047C) and has received support from Boston Children’s Hospital Department of Pediatrics for the Precision Vaccines Program. They have also been named inventor on patent applications regarding adjuvants as adjuvanted vaccines. All other authors report no potential conflicts of interest.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical